NCT02029001 2025-08-07
MOST plus
Centre Leon Berard
Phase 2 Recruiting
Clinical Trials
11 trialsNCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT00777101 2018-08-09
Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer
Puma Biotechnology, Inc.
Phase 2 Completed
NCT00347919 2016-02-25
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00526669 2016-01-29
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
GlaxoSmithKline
Phase 2 Completed
NCT01985893 2016-01-14
THOR
Berufsverband Niedergelassener GynÀkologischer Onkologen in Deutschland e.V.
Phase 2 Withdrawn
NCT00044343 2014-07-10
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin
GlaxoSmithKline
Phase 2 Completed
NCT00967031 2013-01-18
Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases
UNICANCER
Phase 2 Completed
NCT00657137 2012-03-15
APRiCOT-B
Tragara Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00239200 2008-07-30
Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
University of Michigan Rogel Cancer Center
Phase 2 Terminated